Moderna announced that its mRNA-based seasonal influenza vaccine, mRNA-1010, demonstrated a 27% reduction in influenza-like illness compared to a standard marketed vaccine in individuals aged 50 and above. The vaccine showed consistent effectiveness across strains and an acceptable safety profile. These data pave the way for Moderna to pursue FDA approval for the vaccine and potential combination shots targeting both flu and COVID-19, signaling important growth opportunities for the mRNA platform beyond the pandemic.